Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma, Mantle-Cell 11Lymphoma, Large B-Cell, Diffuse 5Leukemia, B-Cell 4Lymphoma 3Lymphoma, Non-Hodgkin 2Leukemia 2Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphatic Diseases 1Heart Failure 1

Interventions

Rituximab 22Lenalidomide 13orelabrutinib 12obinutuzumab 11Cyclophosphamide 9zanubrutinib 8fludarabine 7Magnetic Resonance Spectroscopy 5Bendamustine Hydrochloride 5venetoclax 4Specimen Handling 4Biopsy 4pirtobrutinib 3fludarabine phosphate 3Whole-Body Irradiation 2Vincristine 2Stem Cell Transplantation 2Prednisone 2Mycophenolic Acid 2CT-P10 2Automobiles 2treosulfan 1tafasitamab 1polatuzumab vedotin 1pemigatinib 1loncastuximab tesirine 1ibrutinib 1etoposide phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, B-Cell, Marginal Zone × acalabrutinib × Clear all
NCT04883437 2026-02-09

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Emory University

Phase 2 Recruiting
49 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoproliferative Disorders, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡